Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.

@article{MontenegroGarreaud2017MyeloproliferativeNW,
  title={Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.},
  author={Ximena Montenegro-Garreaud and Roberto Miranda and Alexandra Reynolds and Guilin Tang and Sylvia A. Wang and Mariko Yabe and Wei Wang and Lianghua Fang and Carlos E Bueso-Ramos and Pei – Fen Lin and L Jeffrey Medeiros and Xinyan Y Lu},
  journal={Human pathology},
  year={2017},
  volume={65},
  pages={
          147-156
        }
}
Rearrangements of FGFR1 result in the 8p11 myeloproliferative syndrome, a group of rare diseases that features a myeloproliferative neoplasm (MPN) that commonly progresses to lymphoblastic leukemia/lymphoma or acute myeloid leukemia. The most common partner of FGFR1 is ZMYM2, and patients with the ZMYM2-FGFR1 fusion often present with MPN and T-lymphoblastic lymphoma. There are 14 other partners that can fuse with FGFR1, and of interest is the BCR-FGFR1 fusion that results from t(8;22)(p11.2… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 18 times. VIEW TWEETS